NO20084262L - Nye 1,2,3,4-tetrahydrokinoksalinderivater som har glukokortikoidreseptorbindende aktivitet - Google Patents

Nye 1,2,3,4-tetrahydrokinoksalinderivater som har glukokortikoidreseptorbindende aktivitet

Info

Publication number
NO20084262L
NO20084262L NO20084262A NO20084262A NO20084262L NO 20084262 L NO20084262 L NO 20084262L NO 20084262 A NO20084262 A NO 20084262A NO 20084262 A NO20084262 A NO 20084262A NO 20084262 L NO20084262 L NO 20084262L
Authority
NO
Norway
Prior art keywords
alkyl
new
binding activity
receptor binding
glucocorticoid receptor
Prior art date
Application number
NO20084262A
Other languages
English (en)
Inventor
Mamoru Matsuda
Toshiyuki Mori
Kenji Kawashima
Masato Nagatsuka
Sachiko Kobayashi
Minoru Yamamoto
Masatomo Kato
Miwa Takai
Original Assignee
Santen Pharmaceutical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Inc filed Critical Santen Pharmaceutical Co Inc
Publication of NO20084262L publication Critical patent/NO20084262L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Formålet med foreliggende oppfinnelse er å syntetisere et nytt 1,2,3,4-tetrahydro-kinoksalinderivat representert ved formel (1) og å finne en farmakologisk virkning til derivatet. I formelen representerer R1 et halogen, et alkyl, sykloalkyl, aryl eller heterosyklisk gruppe, eller lignende; p representerer 0 til 5; R2 representerer et halogen, et alkyl, hydroksyl eller alkoksygruppe eller lignende; q representerer 0 til 2; R3 representerer hydrogen, et alkyl, alkenyl, alkyl-karbonyl eller arylkarbonylgruppe eller lignende; R4 og R5 representerer uavhengig hydrogen, et halogen, en alkyl, alkenyl, alkynyl, sykloalkyl, aryl eller heterosyklisk gruppe eller lignende; R6 representerer hydrogen, en alkyl, alkenyl, alkynyl, sykloalkyl, aryl eller heterosyklisk gruppe eller lignende; A representerer et alkylen; R7 representerer OR8, NR8R9, SR8, S(0)R8, S(0)2R8; og X representerer O eller S.
NO20084262A 2006-03-14 2008-10-10 Nye 1,2,3,4-tetrahydrokinoksalinderivater som har glukokortikoidreseptorbindende aktivitet NO20084262L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006069739 2006-03-14
JP2006255039 2006-08-22
PCT/JP2007/055122 WO2007105766A1 (ja) 2006-03-14 2007-03-14 グルココルチコイド受容体結合活性を有する新規１，２，３，４－テトラヒドロキノキサリン誘導体

Publications (1)

Publication Number Publication Date
NO20084262L true NO20084262L (no) 2008-10-10

Family

ID=38509582

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084262A NO20084262L (no) 2006-03-14 2008-10-10 Nye 1,2,3,4-tetrahydrokinoksalinderivater som har glukokortikoidreseptorbindende aktivitet

Country Status (16)

Country Link
US (2) US8551991B2 (no)
EP (1) EP1995242B1 (no)
KR (2) KR20140063907A (no)
CN (1) CN101400659B (no)
AU (1) AU2007225693A1 (no)
BR (1) BRPI0708767A2 (no)
CA (1) CA2643070C (no)
DK (1) DK1995242T3 (no)
ES (1) ES2396711T3 (no)
MX (1) MX2008011779A (no)
NO (1) NO20084262L (no)
PL (1) PL1995242T3 (no)
PT (1) PT1995242E (no)
RU (1) RU2008140525A (no)
SI (1) SI1995242T1 (no)
WO (1) WO2007105766A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400659B (zh) * 2006-03-14 2012-02-29 参天制药株式会社 具有糖皮质激素受体结合活性的新型1，2，3，4-四氢喹喔啉衍生物
EP2151436B1 (en) * 2007-05-29 2013-04-24 Santen Pharmaceutical Co., Ltd Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
WO2009035068A1 (ja) * 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. 新規１，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体
JP2009084273A (ja) * 2007-09-13 2009-04-23 Santen Pharmaceut Co Ltd １，３，３−トリメチル−７−フェニル−３，４−ジヒドロ−１ｈ−キノキサリン−２−オン誘導体からなるグルココルチコイド受容体アゴニスト
GEP20135804B (en) * 2008-09-12 2013-04-10 Santen Pharmaceutical Co Ltd Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester introduced therein as substituent
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9676703B2 (en) 2013-08-09 2017-06-13 Santen Pharmaceutical Co., Ltd. Production method for 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and intermediate for said production method
US10047075B2 (en) * 2014-01-24 2018-08-14 Purdue Pharma L.P. Pyridines and pyrimidines and use thereof
CN104628661A (zh) * 2015-02-05 2015-05-20 北京理工大学 一类喹喔啉酮衍生物作为醛糖还原酶抑制剂的结构、制备方法及用途
CN105037425B (zh) * 2015-07-28 2017-06-20 华侨大学 一种喹喔啉‑2(1h)‑酮c‑3位膦酸化合物的合成方法
HK1252159A1 (zh) 2015-08-25 2019-05-17 参天制药株式会社 [4-(1，3，3-三甲基-2-氧代-3，4-二氢-1h-喹喔啉-7-基)苯氧基]乙基氧基化合物或其盐
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
WO2018230713A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
US11093563B2 (en) * 2018-02-05 2021-08-17 Microsoft Technology Licensing, Llc Sharing measured values of physical space parameters
HRP20221020T1 (hr) 2018-07-20 2022-11-11 Grünenthal GmbH Supstituirani derivati triazolo kinoksalina
AR117951A1 (es) 2018-07-20 2021-09-08 Gruenenthal Gmbh Derivados de triazolquinoxalina adicionalmente sustituidos
CN109574811B (zh) * 2018-11-22 2021-12-24 中山大学 一种阿尼芬净侧链中间体对戊氧基三联苯甲酸的制备方法
CN111138398A (zh) * 2019-12-31 2020-05-12 陕西国际商贸学院 一种2-(2-氨基-3-甲氧苯基)色酮的合成工艺
WO2021144440A1 (en) * 2020-01-17 2021-07-22 Grünenthal GmbH Quinoxaline derivatives as modulators of the glucocorticoid receptor
ES2976780T3 (es) * 2020-01-17 2024-08-08 Gruenenthal Gmbh Derivados de quinoxalina
CN115819356B (zh) * 2022-03-16 2025-05-06 中国中医科学院中药研究所 一种制备四氢喹喔啉类化合物的方法
CN115160348B (zh) * 2022-07-06 2024-06-21 中山大学 一种光照下无金属催化的芳香c-h键直接硼化反应的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369057B1 (en) 1991-04-15 2002-04-09 Aventis Pharma Deutschland Gmbh Quinoxalines, processes for their preparation and their use
ES2164639T3 (es) 1991-04-15 2002-03-01 Aventis Pharma Gmbh Quinoxalinas, procedimiento para su preparacion y su empleo.
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
CA2523743A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
US7235662B2 (en) 2003-06-11 2007-06-26 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
RU2007107177A (ru) * 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
US8017775B2 (en) 2005-09-14 2011-09-13 Santen Pharmaceutical Co., Ltd. 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity
JP5054996B2 (ja) 2006-03-14 2012-10-24 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規１，２，３，４−テトラヒドロキノキサリン誘導体
CN101400659B (zh) 2006-03-14 2012-02-29 参天制药株式会社 具有糖皮质激素受体结合活性的新型1，2，3，4-四氢喹喔啉衍生物
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
KR20090086539A (ko) 2006-11-14 2009-08-13 산텐 세이야꾸 가부시키가이샤 (치환 페닐 또는 치환 복소환) 카르보닐옥시 저급 알킬기와 에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2-디히드로퀴놀린 유도체
WO2008111632A1 (ja) 2007-03-13 2008-09-18 Santen Pharmaceutical Co., Ltd. ２，２，４－トリメチル－６－フェニル－１，２－ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト
EP2151436B1 (en) * 2007-05-29 2013-04-24 Santen Pharmaceutical Co., Ltd Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
JP2009084273A (ja) 2007-09-13 2009-04-23 Santen Pharmaceut Co Ltd １，３，３−トリメチル−７−フェニル−３，４−ジヒドロ−１ｈ−キノキサリン−２−オン誘導体からなるグルココルチコイド受容体アゴニスト
WO2009035068A1 (ja) 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. 新規１，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体

Also Published As

Publication number Publication date
US20130303537A1 (en) 2013-11-14
CN101400659B (zh) 2012-02-29
RU2008140525A (ru) 2010-04-27
EP1995242B1 (en) 2012-11-07
BRPI0708767A2 (pt) 2011-06-14
MX2008011779A (es) 2008-09-25
PT1995242E (pt) 2012-11-22
CN101400659A (zh) 2009-04-01
EP1995242A1 (en) 2008-11-26
EP1995242A4 (en) 2010-08-04
KR20140063907A (ko) 2014-05-27
WO2007105766A1 (ja) 2007-09-20
KR101426966B1 (ko) 2014-08-06
US8551991B2 (en) 2013-10-08
US20090111807A1 (en) 2009-04-30
KR20080100281A (ko) 2008-11-14
ES2396711T3 (es) 2013-02-25
AU2007225693A1 (en) 2007-09-20
US8975256B2 (en) 2015-03-10
PL1995242T3 (pl) 2013-03-29
CA2643070A1 (en) 2007-09-20
SI1995242T1 (sl) 2013-01-31
DK1995242T3 (da) 2012-12-17
CA2643070C (en) 2016-01-26

Similar Documents

Publication Publication Date Title
NO20081787L (no) Nye 1-3-dihydrokinolinderivat som har glukocorticosteroid-reseptorbindingsaktivitet
NO20085140L (no) Nye indazolderivater som har spiro ringstruktur i sidekjede
SV2009003233A (es) Derivados de 2-(1-fenil -5- hidroxi -4alfa-metil-hexahidrociclopenta (f)indazol-5- il)etil fenilo como ligandos del receptor glucocorticoide
PE20090420A1 (es) Compuestos de piperazina con accion herbicida
NO20084983L (no) Aminderivat med NPY Y5 reseptorantagonistaktivitet
NO20083248L (no) Imidazoler som GABA-B reseptormodulatorer
NO20076010L (no) Heterosyklisk forbindelse
NO20061416L (no) Pyrimidotiofenforbindelser
NO20071873L (no) DNA-PK inhibotorer.
NO20084350L (no) Heterocykliske amider til anvendelse som farmasoytika
NO20070607L (no) CETP-inhibitorer.
NO20080717L (no) Oksimderivat og fremgangsmate for fremstilling av dette
EA200900635A1 (ru) Антагонисты прогестеронового рецептора
CL2012001171A1 (es) Procedimiento para la preparacion del ester n-[[2-[[[4-[[[(hexiloxicarbonil)]4-amino]iminometil]fenil]amino]metil]1-alquil-1h-benzimidazol-5-il]carbonil]n-2-piridinil-etilico de beta-alanina; y uno de los compuestos intermediarios considerados.
MX2009008465A (es) Nuevas 2-aminooxazolinas como ligandos de taar1.
PE20070195A1 (es) Inhibidores de histona deacetilasa
NO20092689L (no) Quinuclidinolderivater som muskarin reseptorantagonister
NO20072409L (no) Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser
MY150269A (en) Novel phenylpyrrole derivative
UY32027A (es) Derivados de acilaminobenzamida novedosos
NO20083243L (no) Pyrazoler for behandling av GERD og IBS
IN2012DN00770A (no)
NO20083244L (no) Heterosykliske GABA-B modulatorer
PE20120809A1 (es) Antagonistas ccr3 arilsulfonamida 2,5-disustituidos
WO2009035068A1 (ja) 新規１，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application